The health ministry has started considering ways to promote the use of follow-on products of very expensive original biological drugs. https://www.japantimes.co.jp/news/2025/10/26/japan/science-health/follow-on-biologics/?utm_medium=Social&utm_source=mastodon #japan #sciencehealth #medicine #mhlw #pharmaceuticals
Boardroom drama at Wegovy-maker Novo Nordisk has laid bare the company's biggest challenge: how to better tap into America's mass market for weight-loss drugs. https://www.japantimes.co.jp/business/2025/10/22/companies/novo-nordisk-board-us-consumers/?utm_medium=Social&utm_source=mastodon #business #companies #wegovy #pharmaceuticals #novonordisk
AstraZeneca's deal with U.S. President Donald Trump to lower drug costs for Americans and shield the drugmaker from import tariffs was the culmination of efforts stretching back to November last year, sources have said. https://www.japantimes.co.jp/business/2025/10/14/companies/astrazeneca-medicine-deal-trump/?utm_medium=Social&utm_source=mastodon #business #companies #astrazeneca #pharmaceuticals #us #donaldtrump #trade #tariffs #republicans
AstraZeneca and Daiichi Sankyo’s drug Datroway has significantly improved survival and delayed the progression of breast cancer in patients with a particularly hard to treat form of the disease, AstraZeneca has said. https://www.japantimes.co.jp/business/2025/10/07/companies/astrazeneca-breast-cancer/?utm_medium=Social&utm_source=mastodon #business #companies #astrazeneca #daiichisankyo #health #cancer #medicine #pharmaceuticals
The planned interventions in the American economy reverse decades of hands-off approach to private enterprise. https://www.japantimes.co.jp/business/2025/10/05/trump-white-house-deals-midterms/?utm_medium=Social&utm_source=mastodon #business #us #donaldtrump #pharmaceuticals #medicine #ai #mining #energy
U.S. President Donald Trump’s new tariffs on pharmaceutical imports will not apply to countries with negotiated agreements with the U.S. that contain provisions on drugs, according to a White House official. https://www.japantimes.co.jp/business/2025/09/27/economy/pharmaceutical-tariffs-wont-apply-japan/?utm_medium=Social&utm_source=mastodon #business #economy #tariffs #donaldtrump #trade #pharmaceuticals #us #japaneseeconomy #usjapanrelations
A twice-a-year injection, recently approved for HIV prevention in the U.S. and the European Union, helps solve the problem of adherence, Gilead argues. https://www.japantimes.co.jp/business/2025/09/22/companies/gilead-twice-a-year/?utm_medium=Social&utm_source=mastodon #business #companies #hiv #medicine #gilead #pharmaceuticals #nationalhealthcare
Trump administration officials plan to link the active ingredient in Tylenol to autism Monday, The Washington Post reported, citing unnamed people familiar with the matter. https://www.japantimes.co.jp/news/2025/09/22/world/politics/trump-link-tylenol-autism/?utm_medium=Social&utm_source=mastodon #worldnews #politics #tylenol #autism #pharmaceuticals #us #donaldtrump #health #medicine
Senators Demand Names of Foreign Drugmakers Skirting FDA Import Bans
---
Citing a recent ProPublica investigation, Rick Scott, R-Fla., and Kirsten Gillibrand, D-N.Y., said they had “urgent concerns” about the agency’s oversight of foreign drugmakers and whether medications coming into the U.S. are safe.
https://www.propublica.org/article/senators-letter-fda-drug-import-bans?utm_source=mastodon&utm_medium=social&utm_campaign=mastodon-post
In fast-aging Japan, struggles with dementia are a common story. But researchers hope that future breakthroughs will help them rewrite the ending. https://www.japantimes.co.jp/news/2025/09/17/japan/science-health/dementia-research/?utm_medium=Social&utm_source=mastodon #japan #sciencehealth #aging #elderly #mentalhealth #alzheimer039s #medicine #pharmaceuticals #dementia #lecanemab #donanemab
Takeda Pharmaceutical’s experimental narcolepsy drug has significantly improved outcome for patients in late-stage clinical trials, and could become the first treatment to target the disorder's root cause. https://www.japantimes.co.jp/news/2025/09/09/japan/science-health/takeda-narcolepsy/?utm_medium=Social&utm_source=mastodon #japan #sciencehealth #takeda #health #pharmaceuticals #sleep
After grappling with high production costs as a result of soaring energy prices in the wake of Russia's invasion of Ukraine, Europe's chemical producers are faced with fresh turmoil from U.S. import tariffs. https://www.japantimes.co.jp/business/2025/09/04/markets/trump-tariffs-europe-chemicals/?utm_medium=Social&utm_source=mastodon #business #markets #pharmaceuticals #eu #germany #us #donaldtrump #trade #tariffs #chemicals
Chinese companies are racing to make generic versions of popular branded weight-loss drugs after regulators restricted sale of cheap copies, slowing demand for raw ingredients the firms supplied over the past two years. https://www.japantimes.co.jp/business/2025/09/03/companies/chinese-companies-generics-us-weight/?utm_medium=Social&utm_source=mastodon #business #companies #china #pharmaceuticals #wegovy #elililly#novonordisk #fda
Shares in Chugai Pharmaceutical, Japan's largest drugmaker, have tumbled the most since 1977 after late-stage trial data on an obesity drug it licensed to Eli Lilly & Co. showed disappointing results. https://www.japantimes.co.jp/business/2025/08/08/companies/chugai-shares-sink/?utm_medium=Social&utm_source=mastodon #business #companies #chugai #health #pharmaceuticals #obesity
A health ministry panel approved a plan to cut the price of Lecanemab, an Alzheimer's drug that Japanese drugmaker Eisai and U.S. industry peer Biogen codeveloped, by 15% in Japan starting Nov. 1. https://www.japantimes.co.jp/news/2025/08/07/japan/science-health/japan-alzheimer-drug-price-cut/?utm_medium=Social&utm_source=mastodon #japan #sciencehealth #alzheimer039s #medicine #pharmaceuticals#eisai #health
A Kyoto University research team has developed a pain-reliever that is comparable to morphine but does not have serious side effects. https://www.japantimes.co.jp/news/2025/08/05/japan/japan-new-painkiller-comparable-to-morphine/?utm_medium=Social&utm_source=mastodon #japan #health #medicine #pharmaceuticals #cancer #kyotouniversity
Japan's Kobayashi Pharmaceutical will accelerate efforts to reform its corporate culture marked by workers' reliance on top management, Chairman Yoshihito Ota has said. https://www.japantimes.co.jp/business/2025/08/04/companies/kobayashi-pharmaceutical-corporate-culture-reform/?utm_medium=Social&utm_source=mastodon #business #companies #kobayashipharmaceutical #osaka #pharmaceuticals #health #corporategovernance
The FDA is cracking down on a generic drugmaker that was the subject of a ProPublica investigation last year, citing problems with safety tests that delayed the recall of a faulty medicine linked to deaths in the U.S.
https://www.propublica.org/article/fda-letter-glenmark-pharmaceuticals?utm_source=mastodon&utm_medium=social&utm_campaign=mastodon-post
The biotechnology industry is experiencing a tectonic shift, driven by Chinese drugmakers who have come a long way from their copycat days to challenge Western dominance on innovation. https://www.japantimes.co.jp/business/2025/07/14/tech/china-biotech-world-drug-pipeline/?utm_medium=Social&utm_source=mastodon #business #tech #biotech #pharmaceuticals #china #medicine
U.S. President Donald Trump has vowed to push forward with his aggressive tariff regime, stressing he would not offer additional extensions on country-specific levies set to now hit in early August. https://www.japantimes.co.jp/business/2025/07/09/markets/trump-tariff-copper-drugs/?utm_medium=Social&utm_source=mastodon #business #markets #us #donaldtrump #trade #tariffs #republicans #copper #pharmaceuticals